Breaking News, Collaborations & Alliances

MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing

The ExPERT and IRO platforms were integrated to improve the yield of gene-edited T cells and shorten manufacturing timelines.

By: Rachel Klemovitch

Assistant Editor

MaxCyte, Inc., a cell-engineering focused company of next-generation cell therapeutics, and Oribiotech Ltd.(Ori), an advanced cell and gene therapy (CGT) manufacturing technology company, entered a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT platform and proven Flow Electroporation technology, with Ori’s innovative next-generation cell therapy manufacturing platform, IRO (ee-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters